GemVax’s highly promising Phase II Alzheimer’s disease clinical trial results targeting telomerase published in prestigious Alzheimer’s Research & Therapy’ journal
GemVax & KAEL Co., Ltd. (Korea: 082270) (“GemVax”) has announced that a paper on GV1001, a novel Alzheimer’s treatment based on telomerase modification, was published on March 26th in the SCI-grade international journal ‘Alzheimer’s Research & Therapy’. The paper is titled ‘Efficacy and safety of GV1001 in patients with moderate-to-severe Alzheimer’s already receiving donepezil: a phase 2…
